Literature DB >> 998506

Propranolol-induced reduction of signs of ischemic injury during acute myocardial infarction.

H K Gold, R C Leinbach, P R Maroko.   

Abstract

The effect of intravenous administration of propranolol (3 to 10 mg) was studied in 12 patients with acute anterior transmural myocardial infarction within the first 8 hours from the onset of pain. Criteria for inclusion in the study were persistence of ischemic pain, S-T segment elevation of 0.3 or more mg in at least two standard precordial leads, heart rate of 80 or more beats/min, mean arterial pressure of 75 or more mm Hg and cardiac index of 2.5 or more liters/min per m2. Within 30 minutes of administration of propranolol, the sum of S-T segment elevations from leads V1 through V6 (sigmaST6) and the average S-T segment elevation over the left precordium recorded from multiple unipolar leads (ST) decreased significantly by 40 and 39%, respectively. At the same time, there was a significant reduction in heart rate (from 100+/-3 [standard error of the mean] to 79+/-4 beats/min), mean arterial pressure (from 112+/-6 to 95+/-5 mm Hg) and cardiac output (from 6.1+/-0.3 to 4.1+/-0.3 liters/min). Pulmonary capillary wedge pressure remained unaltered. Four hours later the hemodynamic variables had returned to control level, but the beneficial effect on myocardial injury persisted. These electrocardiographic changes were accompanied by resolution of ischemic pain and cessation of ventricular arrhythmias. The effects of propranolol were more pronounced in patients with angiographically demonstrable flow to the affected area of myocardium. Thus, administration of propranolol in the early hours of myocardial infarction can significantly reduce the signs of myocardial ischemic injury without excessively depressing myocardial function.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 998506     DOI: 10.1016/0002-9149(76)90344-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

Review 1.  Beta-adrenoceptor blocking drugs and acute myocardial infarction.

Authors:  B N Singh
Journal:  Drugs       Date:  1978-03       Impact factor: 9.546

Review 2.  Treatment of pain in acute myocardial infarction.

Authors:  J Herlitz; A Hjalmarson; F Waagstein
Journal:  Br Heart J       Date:  1989-01

3.  The effects of trapidil and propranolol on platelet aggregation and prostacyclin-thromboxane balance following acute myocardial infarction in rabbits.

Authors:  X A Lu; H Ling; C R Dong; J P Ouyang
Journal:  J Tongji Med Univ       Date:  1988

Review 4.  Non-invasive assessment of the effects of drugs on acute myocardial infarct size in man.

Authors:  D Maclean
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

5.  Limitation of myocardial infarct size. Present status.

Authors:  S Yusuf; P Sleight
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

Review 6.  Secondary prevention after myocardial infarction: effects of beta blocking agents and calcium antagonists.

Authors:  P Depelchin; J Sobolski; M Jottrand; C Flament
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

7.  Comparison of the effects of acute and chronic beta-blockade on infarct size in the dog after circumflex occlusion.

Authors:  D E Euler; P J Hughes; P J Scanlon
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

8.  Hemodynamic monitoring in acute myocardial infarction.

Authors:  J A Cairns
Journal:  Can Med Assoc J       Date:  1979-10-06       Impact factor: 8.262

9.  Reduction of myocardial ischemic injury with sublingual isosorbide dinitrate.

Authors:  S K Durairaj; K Venkataraman; L J Haywood
Journal:  J Natl Med Assoc       Date:  1980-11       Impact factor: 1.798

10.  Local beta-adrenergic blockade does not reduce infarct size after coronary occlusion and reperfusion: a study of coronary venous retroinfusion of metoprolol.

Authors:  S Kobayashi; H Tadokoro; L Rydén; P O Sjöquist; R V Haendchen; E Corday
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.